Boehringer Ingelheim has appointed Lars Dreesmann, Ph.D., as President of the company’s U.S. biopharmaceutical development and manufacturing business, Boehringer Ingelheim Fremont, Inc. Most recently, Dr. Dreesmann was Head of Global Quality Systems & Product Compliance Biopharma for Boehringer Ingelheim, a role he has held since January 2019. In his new role, Dr. Dreesmann will report to Jean-Michel Boers, U.S. Country Managing Director, President & CEO, Boehringer Ingelheim.

Since joining the company in 2001, Dr. Dreesmann has held a series of leadership roles with increasing levels of responsibility within the company’s Biopharmaceuticals headquarters in Germany. His research has been published in multiple scientific and medical journals and he holds a patent in the field of neurobiology.

“We are extremely pleased to have Lars take on the leadership of our US biopharmaceuticals business during this critical time of growth,” said Jean-Michel Boers, US Country Managing Director, President & CEO, Boehringer Ingelheim. “He is a proven leader with a keen scientific mind and a deep understanding of our business, which he gained during his more than a dozen years in Boehringer Ingelheim’s global Biopharmaceuticals headquarters. We wish Lars much success in his new role.”